These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 14512794)

  • 1. Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2.
    Nagayama H; Sato K; Morishita M; Uchimaru K; Oyaizu N; Inazawa T; Yamasaki T; Enomoto M; Nakaoka T; Nakamura T; Maekawa T; Yamamoto A; Shimada S; Saida T; Kawakami Y; Asano S; Tani K; Takahashi TA; Yamashita N
    Melanoma Res; 2003 Oct; 13(5):521-30. PubMed ID: 14512794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1-alpha,25-Dihydroxyvitamin D3 (1,25(OH)(2)D(3)) hampers the maturation of fully active immature dendritic cells from monocytes.
    Canning MO; Grotenhuis K; de Wit H; Ruwhof C; Drexhage HA
    Eur J Endocrinol; 2001 Sep; 145(3):351-7. PubMed ID: 11517017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Chorionic Villous Mesenchymal Stem Cells Modify the Functions of Human Dendritic Cells, and Induce an Anti-Inflammatory Phenotype in CD1+ Dendritic Cells.
    Abomaray FM; Al Jumah MA; Kalionis B; AlAskar AS; Al Harthy S; Jawdat D; Al Khaldi A; Alkushi A; Knawy BA; Abumaree MH
    Stem Cell Rev Rep; 2015 Jun; 11(3):423-41. PubMed ID: 25287760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.
    Escobar A; López M; Serrano A; Ramirez M; Pérez C; Aguirre A; González R; Alfaro J; Larrondo M; Fodor M; Ferrada C; Salazar-Onfray F
    Clin Exp Immunol; 2005 Dec; 142(3):555-68. PubMed ID: 16297169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate.
    Vilella R; Benítez D; Milà J; Lozano M; Vilana R; Pomes J; Tomas X; Costa J; Vilalta A; Malvehy J; Puig S; Mellado B; Martí R; Castel T
    Cancer Immunol Immunother; 2004 Jul; 53(7):651-8. PubMed ID: 14999431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of canine monocyte-derived dendritic cells with phenotypic and functional differentiation.
    Wang YS; Chi KH; Liao KW; Liu CC; Cheng CL; Lin YC; Cheng CH; Chu RM
    Can J Vet Res; 2007 Jul; 71(3):165-74. PubMed ID: 17695590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100.
    Panelli MC; Wunderlich J; Jeffries J; Wang E; Mixon A; Rosenberg SA; Marincola FM
    J Immunother; 2000; 23(4):487-98. PubMed ID: 10916759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.
    Oosterwijk-Wakka JC; Tiemessen DM; Bleumer I; de Vries IJ; Jongmans W; Adema GJ; Debruyne FM; de Mulder PH; Oosterwijk E; Mulders PF
    J Immunother; 2002; 25(6):500-8. PubMed ID: 12439347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility to generate monocyte-derived dendritic cell from coculture with melanoma tumor cells in the presence of granulocyte/macrophage colony-stimulating factor (GM-CSF) and interleukin-4.
    Kim YT; Hersh EM; Trevor KT
    Am J Reprod Immunol; 2003 Apr; 49(4):230-8. PubMed ID: 12852497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial).
    Ridolfi L; de Rosa F; Fiammenghi L; Petrini M; Granato AM; Ancarani V; Pancisi E; Soldati V; Cassan S; Bulgarelli J; Riccobon A; Gentili G; Nanni O; Framarini M; Tauceri F; Guidoboni M
    BMJ Open; 2018 Aug; 8(8):e021701. PubMed ID: 30082356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of CXC chemokine platelet factor 4 on differentiation and function of monocyte-derived dendritic cells.
    Xia CQ; Kao KJ
    Int Immunol; 2003 Aug; 15(8):1007-15. PubMed ID: 12882838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial.
    Trepiakas R; Berntsen A; Hadrup SR; Bjørn J; Geertsen PF; Straten PT; Andersen MH; Pedersen AE; Soleimani A; Lorentzen T; Johansen JS; Svane IM
    Cytotherapy; 2010 Oct; 12(6):721-34. PubMed ID: 20429791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of autologous serum on CD34(+) or monocyte-derived dendritic cells.
    Loudovaris M; Hansen M; Suen Y; Lee SM; Casing P; Bender JG
    J Hematother Stem Cell Res; 2001 Aug; 10(4):569-78. PubMed ID: 11522239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective induction of melanoma-antigen-specific CD8+ T cells via Vγ9γδT cell expansion by CD56(high+) Interferon-α-induced dendritic cells.
    Nieda M; Terunuma H; Eiraku Y; Deng X; Nicol AJ
    Exp Dermatol; 2015 Jan; 24(1):35-41. PubMed ID: 25363560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine.
    O'Rourke MG; Johnson M; Lanagan C; See J; Yang J; Bell JR; Slater GJ; Kerr BM; Crowe B; Purdie DM; Elliott SL; Ellem KA; Schmidt CW
    Cancer Immunol Immunother; 2003 Jun; 52(6):387-95. PubMed ID: 12682787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient presentation of tumor idiotype to autologous T cells by CD83(+) dendritic cells derived from highly purified circulating CD14(+) monocytes in multiple myeloma patients.
    Ratta M; Curti A; Fogli M; Pantucci M; Viscomi G; Tazzari P; Fagnoni F; Vescovini R; Sansoni P; Tura S; Lemoli RM
    Exp Hematol; 2000 Aug; 28(8):931-40. PubMed ID: 10989194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monocyte derived dendritic cells have reduced expression of co-stimulatory molecules but are able to stimulate autologous T-cells in patients with MDS.
    Davison GM; Novitzky N; Abdulla R
    Hematol Oncol Stem Cell Ther; 2013 Jun; 6(2):49-57. PubMed ID: 23714180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
    Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE
    Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy of malignant melanoma with tumor lysate-pulsed autologous monocyte-derived dendritic cells.
    Kim DS; Kim DH; Goo B; Cho YH; Park JM; Lee TH; Kim HO; Kim HS; Lee H; Lee JD; Byamba D; Je JH; Lee MG
    Yonsei Med J; 2011 Nov; 52(6):990-8. PubMed ID: 22028165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.